Oren Klaff talks to Greg McKee about Dealmaking in the Psychedelics Space

Greg McKee is Chairman and CEO of Tryp Therapeutics, an early-stage drug development company focused on bringing compounds to market with known activity and safety profiles for the treatment of rare diseases with unmet medical needs. Greg was a co-founder and managing director of Torrent Ventures, a California-focused digital health and medical technology firm that supports promising companies pursuing breakthrough solutions in drug development, genomics, diagnostics, medical devices, drug delivery, and digital health technologies.

During the interview, Klaff asked why the company focuses on psychedelics, how McKee got involved with Tryp and what opportunities the company sees in the psychedelics space.

Listen in to hear the rest!